Body Pharm MOTS-C 10 Vial

To buy MOTS-C peptide in South Africa in 2026, you're choosing between three locally listed formats: lyophilised vials (typically 10 mg), pre-filled pens, and nasal sprays, all sold under a Schedule 4 regulatory framework that treats peptides for human use as prescription-only under the Medicines and Related Substances Act 101 of 1965.

Quick comparison: the three formats at a glance

Format	Typical local price (2026)	Storage before use	Best for
Lyophilised vial (10 mg)	~R1,200–R2,200	−20 °C, dry	Flexible dosing, longest shelf life
Pre-filled pen (5–10 mg)	~R1,500–R3,000	2–8 °C	Convenience, fixed dosing
Nasal spray	~R800–R1,800	2–8 °C	Non-injection research use

Human efficacy data remains largely preclinical as of 2026, with no completed peer-reviewed MOTS-C efficacy trial published.

What You'll Learn

This guide covers how MOTS-C works and what the current research shows, which format suits your needs and how to verify quality, and the regulatory status and practical buying steps in South Africa.

What Is MOTS-C? The Mitochondrial Peptide Explained

MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S rRNA region of mitochondrial DNA. Lee et al. first characterised it in Cell Metabolism in 2015 as a regulator of metabolic homeostasis. Its primary mechanism activates AMP-activated protein kinase (AMPK) via AICAR accumulation, shifting cells toward glucose uptake and fatty acid oxidation.

That AMPK pathway is the same one triggered by exercise and metformin, which is why preclinical literature describes MOTS-C as an "exercise mimetic" with relevance to glucose handling and fat utilisation. A 2023 Frontiers in Endocrinology review confirmed the evidence base remains predominantly preclinical, with animal and cell-culture data showing improved insulin sensitivity and metabolic flexibility but no large randomised human trials published through mid-2026.

Quick facts for buyers

Attribute	Detail
Peptide class	Mitochondrial-derived peptide (MDP)
Length	16 amino acids
Origin	Encoded by 12S rRNA region of mtDNA
Primary mechanism	AMPK activation via AICAR
Approved human indication (2026)	None

No regulator, SAHPRA included, has approved MOTS-C for any human clinical indication as of 2026. If you're buying the lyophilised 10 mg vial, the peptide reconstitution calculator handles the bacteriostatic water maths. The Body Pharm MOTS-C 32 pen is the fixed-dose alternative covered later in this guide.

MOTS-C Research Areas: What the Science Shows in 2026

MOTS-C research in 2026 spans four areas, and all remain predominantly preclinical with no SAHPRA-approved human therapeutic indication. The table below summarises where each area stands.

Research area	What's studied	Evidence level (2026)	SA regulatory approval
Metabolic regulation and insulin sensitivity	Glucose uptake, insulin signalling via AMPK	Preclinical (animal, cell-culture)	None
Fat oxidation and body composition	Shift toward fatty acid oxidation	Preclinical	None
Cellular energy and endurance	Mitochondrial ATP output, exercise capacity	Preclinical plus early-phase human (registered, no published efficacy results)	None
Longevity and mitochondrial health	Circulating MOTS-C levels in ageing and disease cohorts	Observational human, mechanistic	None

Why each area is being investigated

MOTS-C is studied for metabolic regulation because AMPK activation via AICAR accumulation shifts cells toward glucose uptake, the same pathway exercise and metformin engage. The 2023 Frontiers in Endocrinology review confirms the insulin-sensitivity data are animal- and cell-based, with no large randomised human efficacy trial published through mid-2026. Some buyers take this to mean MOTS-C has no effect in humans; human trials take years to complete and publish, so absence of data is not evidence of absence.

MOTS-C is studied for fat oxidation and body composition because the same AMPK signal upregulates fatty acid oxidation in preclinical models. The "metabolic flexibility" framing common to vendor listings reflects that preclinical signal rather than any approved indication.

MOTS-C is studied for cellular energy and endurance because mitochondrial-derived peptides modulate ATP production directly at the mitochondrion. An early-phase human trial of MOTS-C in adults with prediabetes is registered on ClinicalTrials.gov, but no results have been posted.

MOTS-C is studied for longevity signals because circulating peptide levels vary with exercise and age in observational human work. None of this constitutes proof of therapeutic benefit, and any vendor implying otherwise is overreaching.

Before buying, sort out handling: the peptide reconstitution calculator covers the lyophilised vial, while the Body Pharm MOTS-C 32 pen skips reconstitution entirely.

MOTS-C Formats Available in South Africa (2026)

Three MOTS-C formats are sold by South African vendors in 2026: the lyophilised 10 mg vial, the pre-filled injectable pen, and the nasal spray. Each trades off price, handling effort, and bioavailability differently.

Lyophilisation is freeze-drying under vacuum, which removes water and leaves the peptide as a dry powder. Dry MOTS-C is far more stable than solution: it tolerates ambient courier transit for short windows and stores longer once received. The trade-off is that you reconstitute with bacteriostatic water yourself, so accuracy depends on your dosing maths. The Peptide Reconstitution Calculator handles the volume conversions.

Pre-filled pens skip reconstitution entirely. They ship as a sterile solution in a multi-dose device with click-graduated dosing, which suits buyers who want repeatable doses without syringes or vial work. Total peptide content is usually higher than a single vial, which is why pen pricing per mg can undercut vials despite the higher sticker price.

Nasal sprays are the non-injectable option. Intranasal delivery avoids needles, but peptide bioavailability via the nasal mucosa for a molecule the size of MOTS-C (16 amino acids) is not well characterised in published human work through mid-2026. Dose-for-dose equivalence with injection should not be assumed.

Format	Local example (2026)	Price	Reconstitution
Lyophilised 10 mg vial	BeSkinny Body Pharm MOTS-C 10 mg	R600	Required
Pre-filled pen	Body Pharm MOTS-C 32 Pen	See product page	None
Nasal spray	Non-injectable option (limited SA availability)	Not published	None

Format Comparison Table: Vial vs Pen vs Nasal Spray

Format	Typical Dose per Unit	Indicative 2026 Price (ZAR)	Storage	Reconstitution	COA Available	Cold-Chain Shipped	Best For
Lyophilised vial (Body Pharm 10 mg via BeSkinny)	10 mg total, user-dosed	R600	−20 °C dry; 2–8 °C after reconstitution	Yes (bac water)	Yes	Yes	Researchers comfortable with reconstitution maths
Pre-filled pen (Body Pharm 32 Pen)	Multi-dose, click-graduated	See product page	2–8 °C refrigerated	No	Varies by vendor	Varies by vendor	Convenience-focused buyers wanting repeatable dosing
Nasal spray	Concentration not published	Not published	Cool, dry storage per label	No	Not published	Not published	Buyers with a non-injectable preference, accepting unclear bioavailability

The vial is the cheapest per-mg entry point at R600 for 10 mg, but the Body Pharm MOTS-C 32 Pen wins on convenience for buyers who don't want to handle bacteriostatic water. If you go the vial route, run your volumes through the Peptide Reconstitution Calculator before drawing your first dose.

Prices and specifications are indicative as of 2026 and subject to change without notice. Verify directly with the vendor at point of purchase.

How to Verify Quality: COA, Cold-Chain, and Purity Assays

A legitimate research-grade MOTS-C product clears three checks: a batch-specific third-party certificate of analysis, documented cold-chain handling from vendor to door, and a lyophilised format that survives transit. Miss any one and you're paying for an unknown.

The three non-negotiables

Quality Marker	What to Look For	Why It Matters
Third-party COA	Independent lab name, batch number, HPLC/LC-MS purity %, identity confirmation, endotoxin result	In-house COAs can be self-serving; named external labs are accountable
Cold-chain shipping	Insulated packaging, gel packs, courier service level stated at checkout	Lyophilised MOTS-C is most stable at −20 °C; reconstituted solution holds at 2–8 °C for roughly 7–30 days
Lyophilised format	Dry powder in sealed vial, not pre-mixed liquid	Freeze-dried peptide is dramatically more stable in transit than aqueous solution

A third-party COA is a purity and identity report issued by a lab unrelated to the manufacturer. Ask for the batch-specific document, not a generic template. If a vendor sends a PDF without a lab letterhead, signature, or method description, treat it as marketing.

How I assess quality on this guide

When I evaluate a MOTS-C listing, I rank it on four signals before recommending it: COA availability on request with batch traceability, cold-chain shipping disclosed before checkout, lyophilised format with stated reconstitution guidance, and a published South African business presence. The Body Pharm MOTS-C 10 mg vial at BeSkinny clears all four: third-party assayed, cold-chain dispatched, COA on request. Nasal-spray listings typically publish none of these markers openly.

For buyers weighing convenience against per-mg cost, the Body Pharm MOTS-C 32 Pen ships under the same cold-chain process but skips the reconstitution step entirely.

Schedule 4 Status: What It Means for SA Buyers in 2026

MOTS-C is treated as a Schedule 4 prescription medicine in South Africa under the Medicines and Related Substances Act 101 of 1965 (as amended), which means lawful therapeutic supply requires a valid prescription from a registered medical practitioner and dispensing by a pharmacist or other authorised person. No 2024–2026 Government Gazette adds "MOTS-C" by name to a schedule, so it is regulated under the broader categories for peptide hormones and prescription medicines rather than via a named entry.

The research-use framing, plainly

Vendors that list MOTS-C as "research-grade" or "not for human use" are signalling that the product is not a registered consumer health product and has not been evaluated by SAHPRA for therapeutic claims. The Act makes no special exemption for "research use" purchases by members of the public: if a substance is scheduled, supplying it to the public without a prescription is unlawful regardless of the marketing label. That is the framework. How individual buyers interpret it is between them and their prescriber.

Regulatory note: accurate as of 2026

Item	Position as of 2026
Schedule	Schedule 4 (prescription-only) under Act 101 of 1965
Regulator	SAHPRA (South African Health Products Regulatory Authority)
Registered MOTS-C product in SA	None identified on the SAHPRA register
Lawful therapeutic supply	Prescription from a registered practitioner, dispensed by a pharmacist
"Research use" exemption for the public	None in the Act

Speak to a registered healthcare practitioner about whether MOTS-C is appropriate for you before you buy, and use the peptide reconstitution calculator only once that conversation has happened. If you prefer to skip reconstitution entirely, the Body Pharm MOTS-C 32 Pen is the pre-filled alternative discussed later in this guide.

Body Pharm MOTS-C 10 mg: What You Get from BeSkinny

The BeSkinny listing is a Body Pharm-manufactured 10 mg lyophilised MOTS-C vial priced at R600.00 as of 2026, supplied with a third-party purity and identity assay available on request and cold-chain handled from dispatch. It is sold for laboratory research use only and is not a SAHPRA-registered therapeutic product.

Specs at a glance

Item	Detail
Manufacturer	Body Pharm (South Africa)
Format	Lyophilised powder, single vial
Strength	10 mg per vial
Price (2026)	R600.00
Quality marker	Third-party purity and identity assay; COA on request
Shipping	Cold-chain handled from dispatch, discreet packaging
Payment	Card or EFT
Reconstitution	Bacteriostatic water required (not included)

Practical notes before you check out

The 10 mg vial suits buyers who want flexible dosing across a research protocol and don't mind reconstituting. Run your intended concentration through the Peptide Reconstitution Calculator before you order bacteriostatic water so the volume you buy matches the dose schedule you've planned.

If you'd rather skip reconstitution and work with a fixed-dose device, the Body Pharm MOTS-C 32 Pen is the pre-filled alternative on the same catalogue and is covered in detail further down.

Research-use disclaimer: This product is supplied for in vitro laboratory research. It is not a registered medicine and is not intended for human or veterinary administration. Speak to a registered healthcare practitioner before any use decision.

Next step: Add the vial to cart, or email BeSkinny to request the batch-specific COA before purchase.

MOTS-C and Other Metabolic Peptides: How It Fits

MOTS-C sits apart from the other metabolic peptides on the BeSkinny catalogue because it is a mitochondrial-derived peptide that signals through the AMPK energy-sensing pathway, not through appetite or the growth-hormone axis. That mechanistic difference is the main reason researchers compare it against, rather than substitute it for, the peptides below.

Where each peptide acts

Body Pharm AOD 9604 is a modified fragment of human growth hormone studied for its effect on fat metabolism. The research focus is lipolysis, not cellular energy production.

Body Pharm Ipamorelin 5 is a selective growth-hormone secretagogue. It acts on the pituitary GH axis and is researched for recovery and body-composition endpoints.

Body Pharm Semaglutide 6 Pen is a GLP-1 receptor agonist studied for appetite regulation and glucose handling. It works on gut-brain signalling, not mitochondrial output.

MOTS-C is the only one of the four that originates inside the mitochondrion and modulates AMPK directly. As of mid-2026, human efficacy data for MOTS-C remains limited to early-phase work and mechanistic cohort studies, with no large randomised trial published. Treat the comparison above as context for research planning, not as a stacking protocol.

If you are working with the lyophilised vial, the Peptide Reconstitution Calculator will keep your dosing maths consistent across whichever peptides you run in parallel.

Frequently Asked Questions: MOTS-C in South Africa

Is MOTS-C legal to buy in South Africa?

MOTS-C is sold locally for research purposes, but any peptide intended for human administration falls under the Medicines and Related Substances Act 101 of 1965 as a scheduled medicine, with Schedule 4 substances requiring a valid prescription dispensed by a pharmacist. SAHPRA has not registered MOTS-C for any human indication as of 2026.

What is the difference between a lyophilised vial and a pre-filled pen?

The lyophilised vial is freeze-dried powder you reconstitute with bacteriostatic water, giving you full control over concentration and longer dry-state stability. The Body Pharm MOTS-C 32 Pen ships pre-mixed for convenience but has a shorter in-use window once activated. Use the Peptide Reconstitution Calculator for vial maths.

How should I store MOTS-C after reconstitution?

Reconstituted MOTS-C should be kept at 2–8 °C in the original vial, protected from light, and used within the window stated on the product label (commonly 7–30 days for peptides reconstituted with bacteriostatic water). Avoid repeated freeze-thaw cycles, which degrade peptide integrity. Dry, unreconstituted vials are best stored at −20 °C for long-term stability.

Does Body Pharm MOTS-C come with a COA?

Yes. A Certificate of Analysis for Body Pharm MOTS-C is available on request from BeSkinny as of 2026. Body Pharm does not publish a downloadable batch-specific COA with named laboratory and full analyte panel on its open product pages, so requesting the batch COA in writing before purchase is the practical move.

Is MOTS-C approved for human use in South Africa?

No. As of 2026, MOTS-C has no SAHPRA-approved human clinical indication, and published human efficacy data is limited to early-phase and mechanistic cohort work. It is supplied for laboratory research only, not for self-administration or therapeutic claims.

Key Takeaways

• MOTS-C is a 16-amino-acid mitochondrial peptide that activates AMPK, the same energy-sensing pathway triggered by exercise and metformin, but human efficacy data remains largely preclinical as of 2026.
• Three formats are available in South Africa: lyophilised vials (R600 for 10 mg, requires reconstitution), pre-filled pens (no reconstitution), and nasal sprays (bioavailability unclear).
• Verify quality by requesting a batch-specific third-party COA, confirming cold-chain shipping, and choosing lyophilised format for stability.
• MOTS-C is Schedule 4 in South Africa, meaning lawful therapeutic use requires a valid prescription from a registered practitioner; "research use" labelling does not exempt public sales from this requirement.
• Before buying, consult a registered healthcare practitioner and use the peptide reconstitution calculator if choosing the vial format.

Next Steps

1. Speak to a registered healthcare practitioner about whether MOTS-C is appropriate for your research or health goals.
2. Decide between the lyophilised vial (R600, flexible dosing) and the Body Pharm MOTS-C 32 Pen (convenience, no reconstitution).
3. If you choose the vial, use the Peptide Reconstitution Calculator to plan your concentration and bacteriostatic water volume.
4. Request the batch-specific COA from BeSkinny before checkout to verify third-party purity and identity assay.
5. Place your order and confirm cold-chain shipping at checkout.

References

1. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 2015.
2. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
3. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 2023.
4. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). ClinicalTrials.gov, 2026.
5. Peptide Products — Public Information. SAHPRA, 2024.
6. Medicines and Related Substances Act 101 of 1965. Republic of South Africa / SAHPRA, 1965.